Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

By S. Champiat, O. Lambotte, Emmanuel Barreau, R. Belkhir, A. Berdelou, F. Carbonnel, C. Cauquil, P. Chanson, M. Collins, A. Durrbach and 13 more. Annals of Oncology, 2016

845 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6f7fdc9c00acb9d364605062654a4ee65c9212d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. C. Robert
3. K. Kerr
4. J. Haanen
5. J. Larkin
6. S. Peters
7. F. Carbonnel
8. M. Postow

Citations in the corpus

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “Pericarditis and pericardial effusions have been described as well.(35,115)”
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021, background): “Pericarditis and pericardial effusions have been described as well.(195,196) There has also been a case report of irAE-associated acute coronary syndrome.”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Where the patient’s condition does not improve or there is no imaging improvement after 2 days, additional immunosuppressive strategies should be implemented [55, 70, 71].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Where the patient’s condition does not improve or there is no imaging improvement after 2 days, additional immunosuppressive strategies should be implemented [56, 71, 72].”
• Metformin promotes antitumor immunity via endoplasmic reticulum-associated degradation of PD-L1 (2018, neutral): “Despite these combinations having the potential to improve the outlook for cancer immunotherapy, they can also aggravate immune-related adverse events (irAEs) accompanied by checkpoint inhibition (Callahan et al., 2015; Champiat et al., 2016) or induce severe side effects with the inherent toxicity ”